(Bloomberg) -- Pfizer Inc. shares are set to enter the new year trading near the lowest level in a decade, yet Wall Street is increasingly hesitant to bet on a recovery after the drugmaker issued a disappointing 2024 outlook this week. Most Read from BloombergCiti Shuts Muni Business That Once Was Envy of RivalsOwner of the Philippines’ Largest Malls Says China Feud May Hurt BusinessesRange Rovers Become Thief-Magnets, Causing Prices to TumbleHungary Vetoes Ukraine Aid After EU Agrees on Members
Angel Adegbesan is a business reporter whose work has been featured in top publications such as Fortune, Bloomberg News, Toronto Star, and The Washington Post. With a focus on the financial sector and medical industry, Angel covers topics ranging from biotech stocks and market trends to the impact of pharmaceutical drugs on various industries.